专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060078537A1 Mono-and dual chemokine/cytokine constructs 审中-公开
标题翻译：单 - 和双趋化因子/细胞因子构建体
公开(公告)号：US20060078537A1
公开(公告)日：2006-04-13
申请号：US10499151
申请日：2002-12-20
申请人： Matthias Mack , Detlef Schloendorff
发明人： Matthias Mack , Detlef Schloendorff
IPC分类号： A61K38/19 , A61K48/00 , C07H21/04 , C12P21/02 , C07K14/52
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/523 , C07K16/2812 , C07K2317/34 , C07K2317/622 , C07K2317/77 , C07K2319/00
摘要： The present invention relates to a chemokine construct comprising a scFV anti-CD4 and a RANTES chemokine or a functional fragment thereof, whereby said chemokine construct has the structural domain form of (a) RANTES-linker-(VH) anti-CD4-linker-(VL) anti-CD4; or (b) (VL) anti-CD4-linker-(VH) anti-CD4-linker-RANTES, or (c) (VH) anti-CD4-linker-(VL) anti-CD4-linker-RANTES, whereby in the alternatives (b) and (c), the linker between (VH) anti-CD4 and RANTES or between (VL) anti-CD4 and RANTES does not terminally comprise a methionine, a lysine or an isoleucine directly adjacent to the first amino add of RANTES. Furthermore, polynucleotides encoding these chemokine constructs as well as vectors comprising these polynucleotides are disclosed. The invention also relates to specific uses of these constructs and to pharmaceutical compositions.
摘要翻译：本发明涉及包含scFV抗CD4和RANTES趋化因子或其功能片段的趋化因子构建体，其中所述趋化因子构建体具有结构域形式（a）RANTES-接头 - （VH）抗CD4-连接子 - （VL）抗CD4; 或（b）（VL）抗CD4-接头 - （VH）抗CD4连接体RANTES或（c）（VH）抗CD4-连接体 - （VL）抗CD4-连接体RANTES，其中替代方案（b）和（c）中，（VH）抗CD4和RANTES之间或（VL）抗CD4和RANTES之间的连接体不终止包含与第一个氨基酸直接相邻的甲硫氨酸，赖氨酸或异亮氨酸的RANTES。此外，公开了编码这些趋化因子构建体的多核苷酸以及包含这些多核苷酸的载体。本发明还涉及这些构建体和药物组合物的具体用途。

2. 发明申请

US20120039872A1 IL-3 INHIBITORS IN USE FOR TREATMENT OF RHEUMATOID ARTHRITIS IN AN EARLY STAGE 有权
标题翻译： IL-3抑制剂用于治疗早期阶段的湿疹风湿性关节炎
公开(公告)号：US20120039872A1
公开(公告)日：2012-02-16
申请号：US13132754
申请日：2009-12-04
申请人： Matthias Mack , Hilke Brühl
发明人： Matthias Mack , Hilke Brühl
IPC分类号： A61K39/395 , A61K31/7088 , A61P29/00 , A61K38/02
CPC分类号： A61K38/00 , A61K2039/505 , C07K16/244 , C07K2317/76
摘要： The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in a subject is described.
摘要翻译：描述了使用IL-3抑制剂预防性治疗类风湿性关节炎，用于在早期阶段治疗类风湿性关节炎，早期加重阶段，或作为维持治疗以预防受试者的疾病发作或疾病进展。

3. 发明申请

US20050191702A1 Antibody and chemokine constructs and their use in the treatment of infections of immunological diseases 审中-公开
标题翻译：抗体和趋化因子构建体及其在治疗免疫疾病感染中的应用
公开(公告)号：US20050191702A1
公开(公告)日：2005-09-01
申请号：US10672932
申请日：2003-09-26
申请人： Matthias Mack , Detlef Schlondorff , Michael Spring
发明人： Matthias Mack , Detlef Schlondorff , Michael Spring
IPC分类号： A61K38/00 , A61K47/48 , A61K48/00 , C07K14/52 , C07K16/28 , G01N33/53 , C07H21/04 , C12P21/02
CPC分类号： C07K16/2866 , A61K38/00 , A61K47/642 , A61K48/00 , A61K2039/505 , C07K14/523 , C07K16/2809 , C07K2317/34 , C07K2317/77 , C07K2319/00
摘要： The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.
摘要翻译：本发明涉及包含趋化因子受体结合结构域和T细胞表面多肽或细胞毒素结合结构域的嵌合多肽，例如双特异性抗体，编码它们的核酸，以及制备和使用它们的方法。本发明的嵌合多肽可以包括，结合或附着于细胞毒素。本发明还涉及用于制备和使用它们的药物组合物和方法，包括治疗免疫学疾病，例如自身免疫性疾病，以及针对性地消除细胞，例如T淋巴细胞和潜在感染灵长类动物免疫缺陷病毒的其它细胞，例如人类免疫缺陷病毒，例如HIV-1。

4. 发明授权

US08795656B2 Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody 有权
标题翻译：通过施用抗IL3抗体治疗类风湿性关节炎的方法
公开(公告)号：US08795656B2
公开(公告)日：2014-08-05
申请号：US13132754
申请日：2009-12-04
申请人： Matthias Mack , Hilke Brühl
发明人： Matthias Mack , Hilke Brühl
IPC分类号： A61K39/395 , A61K38/00 , A61K39/00
CPC分类号： A61K38/00 , A61K2039/505 , C07K16/244 , C07K2317/76
摘要： The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in a subject is described.
摘要翻译：描述了使用IL-3抑制剂预防性治疗类风湿性关节炎，用于在早期阶段治疗类风湿性关节炎，早期加重阶段，或作为维持治疗以预防受试者的疾病发作或疾病进展。

5. 发明申请

US20090311273A1 TREATMENT OF MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS 有权
标题翻译：治疗多发性硬化症和/或湿疹风湿性关节炎
公开(公告)号：US20090311273A1
公开(公告)日：2009-12-17
申请号：US12295718
申请日：2007-04-02
申请人： Marco Prinz , Wolfgang Bruck , Alexander Mildner , Matthias Mack
发明人： Marco Prinz , Wolfgang Bruck , Alexander Mildner , Matthias Mack
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505
摘要： The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.
摘要翻译：本发明涉及可以特异性结合趋化因子受体CCR2以产生用于治疗优选灵长类动物或人的受试者中的多发性硬化和/或类风湿性关节炎的药物的抗体的用途。在另一个实施方案中，本发明涉及能够特异性结合趋化因子受体CCR2以产生用于在患有多发性硬化和/或类风湿性关节炎的受试者中消耗单核细胞的药物的抗体的用途。本发明还涉及相应的体外方法和治疗方法。例如，除了与CCR2结合的抗体之外，可以使用与CD14结合的抗体。

6. 发明授权

US09068002B2 Treatment of multiple sclerosis and/or rheumatoid arthritis 有权
标题翻译：治疗多发性硬化症和/或类风湿性关节炎
公开(公告)号：US09068002B2
公开(公告)日：2015-06-30
申请号：US12295718
申请日：2007-04-02
申请人： Marco Prinz , Wolfgang Bruck , Alexander Mildner , Matthias Mack
发明人： Marco Prinz , Wolfgang Bruck , Alexander Mildner , Matthias Mack
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505
摘要： The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.
摘要翻译：本发明涉及可以特异性结合趋化因子受体CCR2以产生用于治疗优选灵长类动物或人的受试者中的多发性硬化和/或类风湿性关节炎的药物的抗体的用途。在另一个实施方案中，本发明涉及能够特异性结合趋化因子受体CCR2以产生用于在患有多发性硬化和/或类风湿性关节炎的受试者中消耗单核细胞的药物的抗体的用途。本发明还涉及相应的体外方法和治疗方法。例如，除了与CCR2结合的抗体之外，可以使用与CD14结合的抗体。

7. 发明申请

US20050136033A9 Method of treating allergen induced airway disease 审中-公开
标题翻译：治疗过敏原诱发气道疾病的方法
公开(公告)号：US20050136033A9
公开(公告)日：2005-06-23
申请号：US10217524
申请日：2002-08-13
申请人： Matthias Mack , Corey Hogaboam
发明人： Matthias Mack , Corey Hogaboam
IPC分类号： A61K38/17 , A61K38/19
CPC分类号： A61K38/1709
摘要： The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, or (d) a cell toxin.
摘要翻译：本发明的特征在于通过向受试者施用包含第一多肽结构域的嵌合多肽来治疗过敏性哮喘的方法，所述第一多肽结构域包含至少一个特异性结合趋化因子受体的部分; （a） - （d）中的至少一个：（a）结合T细胞表面多肽的部分，（b）结合树突状细胞表面多肽的部分的第二多肽结构域，（c）结合细胞毒素的部分，或（d）细胞毒素。

8. 发明授权

US06723538B2 Bispecific antibody and chemokine receptor constructs 失效
标题翻译：双特异性抗体和趋化因子受体构建体
公开(公告)号：US06723538B2
公开(公告)日：2004-04-20
申请号：US09948004
申请日：2001-09-05
申请人： Matthias Mack , Detlef Schlondorff , Michael Spring
发明人： Matthias Mack , Detlef Schlondorff , Michael Spring
IPC分类号： C07K1628
CPC分类号： C07K16/2866 , A61K38/00 , A61K47/642 , A61K48/00 , A61K2039/505 , C07K14/523 , C07K16/2809 , C07K2317/34 , C07K2317/77 , C07K2319/00
摘要： The invention is directed to chimeric polypeptides, e.g., bispecific antibodies, comprising a chemokine receptor binding domain and a T cell surface polypeptide or cell toxin binding domain, nucleic acids that encode them, and methods of making and using them. The chimeric polypeptides of the invention can include, be bound to, or attached to, a cell toxin. The invention is also directed to pharmaceutical compositions and methods for making and using them, including the treatment of immunological disorders, such as autoimmune diseases, and for the targeted elimination of cells, e.g., T lymphocytes and other cells latently infected with a primate immunodeficiency virus, such as a human immunodeficiency virus, e.g., HIV-1.
摘要翻译：本发明涉及包含趋化因子受体结合结构域和T细胞表面多肽或细胞毒素结合结构域的嵌合多肽，例如双特异性抗体，编码它们的核酸，以及制备和使用它们的方法。本发明的嵌合多肽可以包括，结合或附着于细胞毒素。本发明还涉及用于制备和使用它们的药物组合物和方法，包括治疗免疫学疾病，例如自身免疫性疾病，以及针对性地消除细胞，例如T淋巴细胞和潜在感染灵长类动物免疫缺陷病毒的其它细胞，例如人类免疫缺陷病毒，例如HIV-1。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式